PLX4032 mediated melanoma associated antigen potentiation in patient derived primary melanoma cells

Journal of Cancer

Volumn 6, Issue 12, 2015, Pages 1320-1330

  George, Andrea L ^a   Suriano, Robert ^b   Rajoria, Shilpi ^a   Osso, Maria C ^d   Tuli, Neha ^a   Hanly, Elyse ^a   Geliebter, Jan ^a   Arnold, Angelo N ^e   Wallack, Marc ^a,c   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Division of Natural Sciences   (United States)

^c METROPOLITAN HOSPITAL CENTER   (United States)

^d MCDANIEL COLLEGE   (United States)

^e WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

BRAF kinases; MAPK; Melanoma; Melanoma associated antigens; PLX4032; Vaccine

Indexed keywords

B RAF KINASE; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RNA; VEMURAFENIB;

ARTICLE; ASSAY; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; MELANOMA CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84953874042     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11126     Document Type: Article

References (40)

1. Dunn GP, Lewis JS, Sunwoo JB, et al. Spontaneous regression of cutaneous head and neck melanoma: implications for the immunologic control of neoplasia. Head Neck. 2008; 30: 267-272.
2. Printz C. Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst. 2001; 93: 1047-1048.
3. Gattoni-Celli S, Cole DJ. Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol. 1996; 23: 754-758.
4. Suriano R, Rajoria S, George AL, et al. Ex vivo derived primary melanoma cells: Implications for immunotherapeutic vaccines. J of Cancer. 2013; 4: 371-382.
5. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364: 2119-2127.
6. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med. 2005; 3: 10-23.
7. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006; 12: 406-414.
8. Wu M, Hemesath TJ, Takemoto CM, et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 2000; 14: 301-312.
9. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signaling pathways in cancer. Oncogene. 2007; 26: 3279-3290.
10. Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. JEM. 2006; 203: 1651-1656.
11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954.
12. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
13. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010; 70: 5213-5219.
14. Winchester RJ, Wang CY, Gibofsky A, Kunkel HG, Lloyd KO, Old LJ. Expression of la-like antigens on cultured human malignant melanoma cell lines. Proc Natl Acad Sci. 1978; 75: 6235-6239.
15. Kaufmann WK, Nevis KR, Qu P, et al. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol. 2008; 128: 175-187.
16. Benlloch S, Paya A, Alenda C, et al. Detection of BRAF V600E mutation in colorectal cancer; comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn. 2006; 8: 540-543.
17. Nowicki TS, Kummer NT, Iacob C, et al. Inhibition of uPAR and UPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope. 2010; 120: 1383-1390.
18. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res. 2010; 23: 190-200.
19. Suriano R, Rajoria S, George AL, et al. Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. Mol and Clin Oncology. 2013; 1: 466-472.
20. Hoek KS, Schlegel NC, Eichhoff OM, et al. Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res. 2008; 21: 665-676.
21. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995; 270: 16483-16486.
22. Dhawan P, Richmond A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem. 2002; 277: 7920-7928.
23. Lavoie JN, L Allemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44MPAK and regulated by the p38/HGGMAPK pathway. J Biol Chem. 1996; 271: 20608-20616.
24. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene. 1999; 18: 3085-3097.
25. Blanchard DA, Mouharmad S, Auffredou M-T, et al. Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP kinase activation in IL-2 dependent kit 225 T lymphocytes. Oncogene. 2000; 19: 4184-4189.
26. Choudhury GG, Karamitsos C, Hernandez J, et al. PI-3-kinase and MAPK regulate mesangial cell proliferation and migration response to PDGF. AJP-Renal Physiol. 1997; 273: 931-938.
27. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004; 117: 4619-4628.
28. Sekulic A, Haluska P Jr, Miller AJ, et al. Malignant melanoma in the 21st century; the emerging molecular landscape. Mayo Clin Proc. 2008; 83: 825-846.
29. Estrada Y, Dong J, Ossowski L. Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 2009; 22: 66-76.
30. Bentley NJ, Eisen T, Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol. 1994; 14: 7996-8006.
31. Yasumoto K, Mahalingam H, Suzuki H, et al. Transcriptional activation of the melanocyte-specific genes by the human homolog of the mouse Microphthalmia protein. J Biochem. 1995; 118: 874-881.
32. Du J, Miller AJ, Widlund HR, et al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol. 2003; 163: 333-343.
33. Salti GI, Manougian T, Farolan M, et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 2000; 60: 5012-6.
34. Barbee MS, Ogunniyi A, Horvat TZ, et al. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother. 2015; [Epub ahead of print].
35. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015; 37(4): 764-782.
36. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5): 1225-1231.
37. Vella LJ, Pasam A, Dimopoulos N, et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res. 2014; 2(4): 351-360.
38. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008; 13: 2-9.
39. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012; 18: 2039-2047.
40. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454.